Core Viewpoint - Baixinan-B (02185) experienced a significant increase of over 52% in stock price, reaching HKD 9.22 with a trading volume of HKD 98.296 million, following the announcement of its Iberis RDN system receiving a 5-year healthcare qualification in France [1] Group 1: Product Development and Market Expansion - The Iberis RDN system has been granted a 5-year healthcare qualification by French authorities, with the potential for renewal, enhancing the clinical application support system in Europe [1] - The company has also secured clinical application and guideline recommendations in Italy, Germany, and Spain [1] - In July, media reports indicated that the U.S. CMS proposed to include RDN in the healthcare coverage for patients with uncontrolled hypertension [1] Group 2: Clinical Success and Market Potential - In February, Baixinan's subsidiary, Shanghai Antong Medical, completed the first commercial procedure of the Iberis RDN system in Germany [1] - According to CITIC Securities, the RDN procedure shows significant and long-term effective blood pressure reduction, with a simple operation and low complication rates, indicating a broad long-term market potential [1] - The company's RDN products are advancing commercialization simultaneously in domestic and international markets, with a focus on the results of the first year of commercialization in 2025 [1]

消息面上，7月15日，百心安旗下铂睿时Iberis RDN 系统获得法国官方给予为期5年的医保资格（且具备 续签资质），在欧洲临床应用支持体系的进一步完善。此外，公司已经在意大利、德国、西班牙获得临 床应用和指南推荐方案；7月有媒体报道称，美国CMS发布新提案，建议将RDN纳入未控制高血压患者 的医保覆盖范围。 值得注意的是，今年2月，百心安附属上海安通医疗研发的Iberis多极肾动脉射频消融系统(IberisRDN系 统)在德国完成首例商业化手术。中信建投指出，RDN降压效果显著且长期有效，术式操作简单并发症 概率低，长期市场空间广阔；百心安RDN产品目前在国内外同步推进商业化，建议关注公司25年首年 商业化成果。 智通财经APP获悉，百心安-B(02185)尾盘涨超52%，截至发稿，涨52.15%，报9.22港元，成交额9829.61 万港元。 ...

Core Viewpoint - The article highlights the significant advancements in hypertension treatment with the successful clinical application of the Iberis RDN system at Hospital Universitario de Torrejón de Ardoz in Madrid, emphasizing its academic value and clinical potential in treating uncontrolled hypertension [2][5]. Group 1: Technological Innovation - The Iberis RDN system represents a breakthrough in renal denervation (RDN) procedures by utilizing the radial artery for access, which reduces trauma and recovery time compared to traditional femoral artery approaches [5]. - The system employs a unique design with a circular four-electrode ablation mechanism and a <4Fr catheter, allowing for precise adaptation to the complex anatomy of renal arteries, enhancing treatment efficacy [10]. - Integrated features such as wall contact testing, precise temperature control, and safety cut-off functions improve the accuracy and stability of the procedure [10]. Group 2: Clinical Outcomes - A case study reported a 43-year-old patient with hereditary resistant hypertension who experienced significant symptom improvement and reduced medication usage following the RDN procedure, showcasing the system's effectiveness [7]. - The rapid recovery and positive feedback from patients have been noted as redefining the recovery experience for hypertension surgeries [7]. Group 3: Future Prospects - The Iberis RDN technology is expected to benefit Spanish hypertension patients, particularly those with poor drug control or intolerance to multiple medications, providing new treatment pathways [8]. - The recognition of the technology's safety and efficacy by Spanish media supports its potential for broader application, including improvements in arrhythmia management [8]. - Ongoing multi-center clinical practices and evidence development are anticipated to further validate the technology's potential in diverse applications for hypertension treatment [8].